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Adenocarcinoma of the cervical esophagus is a rare tumor, in comparison to adenocarcinoma of the distal esophagus which is on
the rise and is often associated with Barrett’s esophagus. We present a case of aggressive cervical esophageal adenocarcinoma in a
46-year-old female with no endoscopic or histopathologic evidence of Barrett’s esophagus. We discuss the possible etiology of this
tumor and review the treatment options, highlighting the importance of a multidisciplinary approach to the management of this
rare disease.
1.Introduction
Esophageal adenocarcinomas typically arise in the lower
third of the esophagus with a pathogenesis linked to gas-
troesophageal reﬂux disease and subsequent development of
Barrett’s epithelium. However, primary adenocarcinomas in
the cervical esophagus are believed to result from mucosal
“cardiac” glands, submucosal glands, or heterotopic gastric
mucosa. Adenocarcinoma in the cervical esophagus is a rare
tumor with little known about its typical prognosis or
optimal therapy, including ideal surgical management and
use of neoadjuvant or adjuvant chemotherapy and/or radio-
therapy.
2.CaseReport
A 46-year-old Caucasian woman with no signiﬁcant past
medical or family history presented to her primary care
providerwithaone-yearhistoryofsorethroatanddysphagia
to solid foods. She reported a remote smoking history in her
teens and rare alcohol consumption. Workup included a
barium swallow study with a persistent ﬁlling defect in the
upper esophagus measuring 5cm × 1.8cm originating from
the posterior right wall of the esophagus. Diﬀerential diag-
nosis included both benign and malignant lesions of the
upper esophagus. Upper endoscopy with endoscopic ultra-
sound revealed an ulcerated, friable mass extending from
15 to 19cm from the incisors with evidence of invasion
into the muscularis propria and suspicion for regional node
involvement (Figures 1(a) and 1(b)). Biopsies from the
u p p e re n d o s c o p yw e r ep o s i t i v ef o rm o d e r a t e l yd i ﬀerentiated
invasive adenocarcinoma (Figures 2(a) and 2(b)).
The patient was staged as T3N1M0 after a PET/CT of the
neck demonstrated a hypermetabolic esophageal mass with
adjacent right paratracheal and superior mediastinal lym-
phadenopathy. CT scan of the chest, abdomen, and pelvis
were negative for distant metastases. Six weeks of deﬁnitive/
neoadjuvant chemoradiotherapy were delivered according
to the Ilsen regimen (cisplatin 30mg/m2 and irinotecan2 Case Reports in Gastrointestinal Medicine
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Figure 1: (a) Upper endoscopy highlights the close proximity of
the tumor to the upper esophageal sphincter (UES). (b) Endoscopic
ultrasoundshowsinvasionofthetumorintothemuscularispropria
and suspicion for regional node involvement.
65mg/m2 on weeks 1, 2, 4, and 5 of radiation). Radiotherapy
consisted of a total of 64.8Gy to the primary esophageal
tumor and adjacent nodes plus 39.6Gy to superior mediasti-
nal nodes. Follow-up PET/CT 14 weeks after completion of
deﬁnitivechemoradiationtherapyrevealedcontinuedhyper-
metabolic activity in the proximal esophagus and repeat
upper endoscopy revealed residual tumor. Otolaryngology
performedacervicalesophagectomy,lymphnode dissection,
and left radial forearm microvascular free tissue transfer
reconstruction of the cervical esophagus. The pathologic
specimen contained moderately diﬀerentiated adenocarci-
noma of the esophagus undermining the squamous epithe-
lium,withmetastasistotwoofsixparatracheallymphnodes,
butnoevidenceofBarrett’sesophagusoridentiﬁablevestiges
of heterotopic gastric mucosa.
Five months after surgery, she developed diﬃculty with
an anastomotic stricture that was dilated endoscopically and
determined to be a result of local tumor recurrence. Nine
months after the initial surgery, salvage laryngopharyngec-
tomy with a right radial forearm ﬂap reconstruction was
performed. The patient’s course continued with a second
locoregional recurrence ﬁve months after salvage surgery,
necessitating further chemotherapy/limited ﬁeld radiother-
apy (ﬁrst low-dose cisplatin, then capecitabine due to an
urticarial rash, and 50.4Gy). A third recurrence ﬁve months
later in a right subclavicular node was treated with resection
and concurrent capecitabine/limited ﬁeld radiation. Most
recently, she had evidence of multifocal recurrence nearly
(a)
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Figure 2: (a) H&E stain (×40 magniﬁcation) shows moderately
diﬀerentiated adenocarcinoma in the deep mucosa beneath intact
squamous epithelium. (b) H&E stain (×100 magniﬁcation) shows
cribriform glands and micropapillae inﬁltrating stroma of the
lamina propria with moderate cellular atypia.
two years after the initial chemoradiation. She is currently
participating in a phase II clinical trial with an oral Aurora
kinase inhibitor and has stable disease based on radiographic
imaging after six treatment cycles.
3. Discussion
Squamous cell carcinoma predominates in the cervical
esophagus; adenocarcinoma in the cervical esophagus is
extremely rare with, to our knowledge, less than 30 cases
reported in the literature. Adenocarcinoma of the distal
esophagus, in contrast, is common and the relative preva-
lence has been increasing from 1.7% to 10% historically to
upwards of 50% of all malignant tumors of the esophagus in
more recent studies [1, 2]. Reasons for this shift in histology
are not well established, but may be due to the simultaneous
rise in Barrett’s esophagus (BE), which is a risk factor for
distal esophageal adenocarcinoma. Adenocarcinomas of the
cervical esophagus can arise from mucosal “cardiac” glands,
submucosal glands, BE, and heterotopic gastric mucosa
(HGM) [1, 3, 4]. HGM is thought to occur when embry-
ologic bidirectional replacement of the esophageal columnar
epithelium by squamous mucosa fails to be completed.
HGM is most often asymptomatic and found incidentally
during endoscopic procedures for unrelated symptoms inCase Reports in Gastrointestinal Medicine 3
approximately 3.8–10% of the adult population [5, 6]. On
endoscopy as well as pathologic specimen, there was no
evidence of BE in our patient, so it is possible that her tumor
originated from HGM.
No standard therapy exists for primary cervical esoph-
ageal adenocarcinoma. Treatment strategies published in the
few case reports range from endoscopic mucosal resection
to laryngo-pharyngo-esophagectomy with lymph node dis-
section with or without neoadjuvant or adjuvant chemora-
diotherapy. However, the number of cases reported in the
current literature is too small and the details of their staging
and treatment too inconsistent to postulate whether these
tumors have a diﬀerent prognosis than the more common
distal esophageal adenocarcinomas [1]. Our patient pre-
sented with a relatively large, ultrasound-staged T3N1 tumor
with a subsequent clinically aggressive course character-
ized by multiple locoregional recurrences despite combined
modality neoadjuvant therapy with surgery. Our case high-
lights the likelihood that improvements in outcomes will
require the best eﬀorts of a multidisciplinary management of
this rare disease with gastroenterology, otolaryngology, tho-
racic surgery, medical oncology, radiation oncology, and
pathology.
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